|
|
Volumn 38, Issue 6, 1996, Pages 445-454
|
|
Implantable cardioverter-defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmias
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIODARONE;
ANTIARRHYTHMIC AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
PROPAFENONE;
SOTALOL;
ARTICLE;
AUTOMATIC CARDIOVERSION;
BETA ADRENERGIC RECEPTOR BLOCKING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
DEFIBRILLATION;
DEFIBRILLATOR;
DRUG EFFICACY;
HEART VENTRICLE TACHYCARDIA;
HUMAN;
LUNG TOXICITY;
MORTALITY;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
SURVIVAL TIME;
TREATMENT OUTCOME;
ECONOMICS;
REVIEW;
SURVIVAL RATE;
ADRENERGIC BETA-ANTAGONISTS;
AMIODARONE;
ANTI-ARRHYTHMIA AGENTS;
DEFIBRILLATORS, IMPLANTABLE;
HUMANS;
SURVIVAL RATE;
TACHYCARDIA, VENTRICULAR;
TREATMENT OUTCOME;
|
|
EID: 0029664632
PISSN: 00330620
EISSN: None
Source Type: Journal
DOI: 10.1016/S0033-0620(96)80008-9 Document Type: Article |
|
Times cited : (36)
|
|
References (0)
|
